NYSTEX Drug Patent Profile
✉ Email this page to a colleague
When do Nystex patents expire, and what generic alternatives are available?
Nystex is a drug marketed by Savage Labs and is included in one NDA.
The generic ingredient in NYSTEX is nystatin. There are eight drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the nystatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nystex
A generic version of NYSTEX was approved as nystatin by FOUGERA PHARMS on September 23rd, 1982.
Summary for NYSTEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Clinical Trials: | 1 |
Patent Applications: | 97 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NYSTEX at DailyMed |
Recent Clinical Trials for NYSTEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for NYSTEX
US Patents and Regulatory Information for NYSTEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Savage Labs | NYSTEX | nystatin | SUSPENSION;ORAL | 062519-001 | Jul 6, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |